Cover Image
市場調查報告書

腦瘤 - 到2024年的流行病學預測

EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 347929
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
腦瘤 - 到2024年的流行病學預測 EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
出版日期: 2015年12月01日 內容資訊: 英文 42 Pages
簡介

根據American Brain Tumor Association,腦瘤包含惡性、良性有120種以上。全球7大市場上,腦瘤確診的發病數量預計從2014年的55,000件以年率1.3%擴大,2024年達62,000件。

本報告提供彙整腦瘤的概要與風險因素、全球7大市場的趨勢,以及今後的流行病學預測。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險因素和共生病症
  • 全球的趨勢
    • 7大市場發病趨勢
    • 存活率趨勢
  • 預測方法
    • 使用的資訊來源
    • 未使用的資訊來源
    • 預測方法與假設
  • 流行病學的預測:2013∼2023年
    • 確診發病數量
    • 各年齡確診發病數量
    • 性別確診發病數量
    • 年齡標準化確診發病數量
    • 5年確診的患病數量
    • 各類型確診發病數量
  • 考察
    • 流行病學的預測
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER106-15

Primary brain cancer is defined as a malignant neoplasm that originates in the central nervous system (CNS), which consists of the brain and spinal cord, including the brain stem (NCI, 2015). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumors, (ABTA, 2014). The type and severity of a brain tumor is defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth, and only those tumors that are malignant are designated as cancer (NCI, 2015). Primary brain tumors are those that start in the brain and may, in time, migrate elsewhere in the body, while metastatic brain tumors are those that start elsewhere in the body and migrate to the brain or other parts of the CNS.

In the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 55,084 cases in 2014 to 62,226 cases in 2024, at an Annual Growth Rate (AGR) of 1.30%. The US will have the highest number of diagnosed incident cases of brain cancer among the 7MM throughout the forecast period. The five-year diagnosed prevalent cases of brain cancer are also expected to increase from 84,704 cases in 2014 to 89,984 cases in 2024, at an AGR of 0.62%. The US will have the highest number of five-year diagnosed prevalent cases of brain cancer in 2014 and 2024, at 42,104 cases and 46,401 cases, respectively.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). This forecast for brain cancer includes only primary malignant brain tumors originating in the CNS (ICD-10 codes C70-C72).

Scope

  • The brain cancer EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). This report includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma).
  • The brain cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The brain cancer EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global brain cancer market.
  • Quantify patient populations in the global brain cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for brain cancer therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 7MM Incidence Trends
    • 3.3.2. 7MM Trends in Relative Survival
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Brain Cancer (2014-2024)
    • 3.5.1. Diagnosed Incident Cases of Brain Cancer
    • 3.5.2. Age-Specific Diagnosed Incidence of Brain Cancer
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of Brain Cancer
    • 3.5.4. Age-Standardized Diagnosed Incidence of Brain Cancer
    • 3.5.5. Five-Year Diagnosed Prevalent Cases of Brain Cancer
    • 3.5.6. Diagnosed Incident Cases of Brain Cancer by Type
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Description of Brain Cancer Types
  • Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of Brain Cancer
  • Table 3: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer
  • Table 4: 7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 5: 7MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Both Sexes, N (Row %), 2014
  • Table 6: 7MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, All Ages, N (Row %), 2014
  • Table 7: 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Age-Standardized Diagnosed Incidence Rate of Brain Cancer (Cases per 100,000 Population), All Ages, Men, 1998-2007
  • Figure 2: 7MM, Age-Standardized Diagnosed Incidence Rate of Brain Cancer (Cases per 100,000 Population), All Ages, Women, 1998-2007
  • Figure 3: 7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 4: 7MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Both Sexes, N, 2014
  • Figure 5: 7MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, All Ages, N, 2014
  • Figure 6: 7MM, Age-Standardized Diagnosed Incidence of Brain Cancer, All Ages, N, 2014
  • Figure 7: 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 8: 7MM, Diagnosed Incident Cases of Brain Cancer by Type, All Ages, Both Sexes, N, 2014
Back to Top